Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular Medicine in Practice

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaogen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng and Denis J. McCann
Genshi Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-ying Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daohong Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James R. Henry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong-Yu Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaogen Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Zia-Ebrahimi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Bloem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Zhai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Huss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheng-bin Peng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis J. McCann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-11-0306 Published November 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, chemical structure of LY2874455, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)-ethanol. B, a binding model of LY2874455 in the ATP site of FGFR3.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Inhibition of FGF/FGFR- and VEGF/VEGFR2-mediated signaling activities in cells by LY2874455. RT-112 cells, HUVECs, KATO-III cells, and SNU-16 cells were grown and treated with LY2874455 at various concentrations (Materials and Methods). After the treatment, cells were processed and analyzed for p-Erk, p-FGFR2, and p-FRS2 levels (Materials and Methods). Adipose-derived stem cells and human erythroid colony-forming cells were grown, induced with FGF2 or VEGF, and treated with LY2874455 at various concentrations (Materials and Methods). After the treatment, tubes formed were visualized and quantified. A, inhibition of FGF2- and FGF9-induced Erk phosphorylation in HUVECs and RT-112 cells. B, inhibition of FGFR2 phosphorylation in SNU-16 and KATO-III cells. DMSO, dimethyl sulfoxide. C, inhibition of p-FRS2 in SNU-16 and KATO-III cells. D, inhibition of FGF2 (▾)- or VEGF (▪)- induced tube formation.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Inhibition of FGF- and VEGF-induced Erk and VEGFR2 phosphorylation, respectively, in mouse heart tissues by LY2874455. Mice were first treated with LY2874455 at various doses followed by tail vein injection of mouse FGF2 or VEGF (Materials and Methods). After the FGF2 or VEGF treatment, the heart tissues were collected and processed for the analysis of p-Erk and p-VEGFR2 levels by MSD ELISA assays (Materials and Methods). The plasma was also collected for the analysis of the exposures or concentrations of LY2874455 versus p-Erk or p-VEGFR2 levels (Materials and Methods). A, dose-dependent inhibition of p-Erk formation. B, exposure-dependent inhibition of p-Erk formation. C, overlay of exposures versus inhibition of p-Erk and p-VEGFR2 formation.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effects of LY2874455 on blood pressure in rats. Animals were treated and effects on blood pressure were assessed as described in Materials and Methods. Mean arterial blood pressure was measured in rats dosed with 1 mg/kg (A), 3 mg/kg (B), and 10 mg/kg (C) of LY2874455.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Efficacy of LY2874455 in different tumor xenograft models. Mice were subcutaneously implanted with SNU-16, OPM-2, NCI-H460, and RT-112 cells (Materials and Methods). Once tumors grew to about 150 mm3, animals were randomly assigned (6–8 per group) and orally dosed with vehicle alone or LY2874455 at the indicated doses on an once or twice a day dosing schedule for 14 to 21 days (Materials and Methods). The growth of tumors was monitored and measured twice a week. A, SNU-16 tumor xenografts treated with LY2874455 (1.5 and 3 mg/kg once or twice a day). B, OPM-2 tumor xenografts treated with LY2874455 (1.5 and 3 mg/kg twice a day). C, NCI-H460 tumor xenografts treated with LY2874455 (1 and 3 mg/kg once or twice a day). D, RT-112 tumor xenografts treated with LY2874455 (3 mg/kg once or twice a day). QD, once a day; BID, twice a day.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Inhibition of FGFR2 and FRS2 phosphorylation in SNU-16 tumor xenografts by LY2874455. After treatment with LY2874455 at various doses for about 2 weeks, the tumor xenografts derived from SNU-16 (see Fig. 5A) were collected and processed. The levels of p-FGFR2 and p-FRS2 were measured by Western blot analysis and MSD ELISA, respectively (Materials and Methods). A, Western blot analysis of p-FGFR2 levels in the tumors versus dose. B, the intensity of each band corresponding to p-FGFR2 from A was quantified and plotted versus dose. C, MSD ELISA of p-FRS2 levels in the tumors versus dose. QD, once a day; BID, twice a day.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (11)
November 2011
Volume 10, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaogen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng and Denis J. McCann
Mol Cancer Ther November 1 2011 (10) (11) 2200-2210; DOI: 10.1158/1535-7163.MCT-11-0306

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaogen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng and Denis J. McCann
Mol Cancer Ther November 1 2011 (10) (11) 2200-2210; DOI: 10.1158/1535-7163.MCT-11-0306
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • EMT and CSCs in HER2+ Breast Cancer
  • Methylglyoxal Enhances TRAIL Efficacy
  • Sorafenib Induces Reactive Oxygen Species Production
Show more Molecular Medicine in Practice
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement